来源：梅斯医学  原创  2017-12-10

来自英国普利茅斯大学医学院的Simon Rule博士在本次ASH大会有关套细胞淋巴瘤最近治疗进展的专题讨论会中，报告了他们使用伊布替尼（Ibrutinib）治疗复发或难治性套细胞淋巴瘤的连续3.5年跟踪观察治疗效果的最新进展。

研究者通过使用BTK酪氨酸激酶抑制剂伊布替尼（Ibrutinib）以每日口服560mg的剂量持续对370例复发或难治性套细胞淋巴瘤病人进行治疗。通过3.5年来不间断随访这些病人的疾病进程，研究者们发现约四分之一的病人疾病进程得到了明显缓解，约一半的病人依然存活。在这场报告中，Simon Rule博士也对伊布替尼（Ibrutinib）可能引起的副作用进行的分析，包括对血液系统和心血管系统的影响。最后，报告者认为伊布替尼（Ibrutinib）作为治疗复发或难治性套细胞淋巴瘤的一线药物，对于缓解患者疾病进程，延长患者生存时间具有明显的效果。

Simon Rule博士正在进行演讲

 

会场座无虚席

Simon Rule博士的演讲标题ppt

151 Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis

Program: Oral and Poster Abstracts
Type: Oral
Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Mantle Cell Lymphoma, New Therapies

Saturday, December 9, 2017: 12:00 PM

Bldg A, Lvl 4, A411-A412 (Georgia World Congress Center)

Simon Rule, MD^1*, Martin Dreyling, MD, PhD², Andre Goy, MD³,Georg Hess^4*, Rebecca Auer, MD, PhD^5*, Brad S Kahl, MD⁶, Jose Angel Hernandez-Rivas^7*, Anil Londhe, PhD^8*, Fong Clow, ScD⁹, Sanjay Deshpande^8*, Lori Parisi^8* and Michael Wang, BS¹⁰

¹Plymouth University Medical School, Plymouth, United Kingdom
²Department of Medicine III, Klinikum der Universität München, Munich, Germany
³John Theurer Cancer Center, Hackensack Meridian Health, New York, NY
⁴Department of Hematology, Medical Oncology and Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
⁵Barts Cancer Institute, London, United Kingdom
⁶Department of Medicine, Washington University School of Medicine in St. Louis, Saint Louis, MO
⁷Department of Hematology, Hospital Infanta Leonor, Madrid, Spain
⁸Janssen Research & Development, Raritan, NJ
⁹Pharmacyclics, Sunnyvale, CA
¹⁰Department of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX

延伸阅读：伊布替尼治疗复发/难治性套细胞淋巴瘤的长期随访研究

如需了解更多淋巴瘤的前沿信息 

请扫描二维码访问“淋巴瘤亿刻”网站。